And thus ends a fantastic day of the B20 Health Summit in Berlin, where much was shared and learned. Well done to everyone involved for putting on such
an informative and important conference. Looking forward to taking the steps proposed today.
Lessons Learned from the Workshops – Reports by the Chairs:
Moderated by Stormy-Annika Mildner, B20 Germany Sherpa
Scientific innovation to address mental and neurological disorders such as Alzheimer’s is extremely challenging, with therapies requiring more time to
obtain regulatory approval compared with medicines for treating other diseases. These diseases alone affect more than one third of the world’s population
and result in nearly $1 trillion lost in economic productivity and a heavy burden on health systems, caregivers, and families. G20 members need to
lay out incentives for research in mental and neurological disorders, support new research partnerships, care models, and public health campaign to
address these diseases holistically.
A discussion on innovation at the heart of the debate: improving health and well-being for an active generation. Chaired by Kemal Malik, Member of
the Board of Management, Bayer AG, with discussants:
A discussion on global health: improved access to medical care chaired by Roland Göhde, Chairman, German Healthcare Partnership, with discussants:
Discussion on the role of digital health chaired by Walter Märzendorfer, President Diagnostic Imaging, Siemens Healthineers, with discussant:
Discussion on improving pandemic preparedness and response chaired by Frank Gotthardt,Peter Sands, Harvard Kennedy School and Chair of World Bank’s International Working Group on Financing Pandemic Preparedness , with discussants:
Discussion on eliminating Neglected Tropical Diseases by 2020 chaired by Frank Gotthardt, Head of Public Affairs & Corporate Responsibility, Merck,
Discussion on antimicrobial resistance chaired by Benjamin Grosch, Partner & Managing Director Berlin, Boston Consulting Group, with discussants: